|
| 36793435 | Discovery of OICR12694: A Novel, Potent, Selective, and Orally Bioavailable BCL6 BTB Inhibitor. | ACS Med Chem Lett | 2023 |
| 37712569 | Which Small Molecule? Selecting Chemical Probes for Use in Cancer Research and Target Validation. | Cancer Discov | 2023 |
| 37660910 | G protein-receptor kinases 5/6 are the key regulators of GÂ protein-coupled receptor 35-arrestin interactions. | J Biol Chem | 2023 |
| 37354357 | An effective kinase inhibition strategy for metastatic recurrent childhood medulloblastoma. | J Neurooncol | 2023 |
| 37075613 | Targeting tumour-associated macrophages in hodgkin lymphoma using engineered extracellular matrix-mimicking cryogels. | Biomaterials | 2023 |
| 34963044 | Correction to "Design, Synthesis, and Characterization of 4-Aminoquinazolines as Potent Inhibitors of the G Protein-Coupled Receptor Kinase 6 (GRK6) for the Treatment of Multiple Myeloma". | J Med Chem | 2022 |
| 36030052 | G protein-coupled receptor kinase 6 (GRK6) regulates insulin processing and secretion via effects on proinsulin conversion to insulin. | J Biol Chem | 2022 |
| 35089724 | Phenolic Lipids Derived from Cashew Nut Shell Liquid to Treat Metabolic Diseases. | J Med Chem | 2022 |
| 34291633 | Design, Synthesis, and Characterization of 4-Aminoquinazolines as Potent Inhibitors of the G Protein-Coupled Receptor Kinase 6 (GRK6) for the Treatment of Multiple Myeloma. | J Med Chem | 2021 |
| 33542074 | Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies. | Clin Cancer Res | 2021 |
| 34589290 | The PKN1- TRAF1 signaling axis as a potential new target for chronic lymphocytic leukemia. | Oncoimmunology | 2021 |
| 34662547 | Chemical Genetics Screen Identifies COPB2 Tool Compounds That Alters ER Stress Response and Induces RTK Dysregulation in Lung Cancer Cells. | J Mol Biol | 2021 |
| 33939407 | Pharmacological Targeting of Executioner Proteins: Controlling Life and Death. | J Med Chem | 2021 |
| 32778845 | Functional characterization of a PROTAC directed against BRAF mutant V600E. | Nat Chem Biol | 2020 |
| 32094923 | A drug discovery platform to identify compounds that inhibit EGFR triple mutants. | Nat Chem Biol | 2020 |
| 30696771 | Parathyroid hormone initiates dynamic NHERF1 phosphorylation cycling and conformational changes that regulate NPT2A-dependent phosphate transport. | J Biol Chem | 2019 |
| 26952093 | PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma. | J Transl Med | 2016 |
| 27618721 | Identification of RSK and TTK as Modulators of Blood Vessel Morphogenesis Using an Embryonic Stem Cell-Based Vascular Differentiation Assay. | Stem Cell Reports | 2016 |
| 27449082 | Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells. | Oncotarget | 2016 |
| 26916338 | Small molecules reveal an alternative mechanism of Bax activation. | Biochem J | 2016 |
| 27006494 | Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma. | Clin Cancer Res | 2016 |
| 26298497 | Recent progress on MAP kinase pathway inhibitors. | Bioorg Med Chem Lett | 2015 |
| 24487029 | shRNA kinome screen identifies TBK1 as a therapeutic target for HER2+ breast cancer. | Cancer Res | 2014 |
| 25330770 | Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K. | EMBO Mol Med | 2014 |
| 25164867 | Structure and mechanism of action of the hydroxy-aryl-aldehyde class of IRE1 endoribonuclease inhibitors. | Nat Commun | 2014 |
| 23844038 | Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions. | PLoS One | 2013 |
| 24900673 | Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors. | ACS Med Chem Lett | 2013 |
| 23830192 | New small molecule inhibitors of UPR activation demonstrate that PERK, but not IRE1α signaling is essential for promoting adaptation and survival to hypoxia. | Radiother Oncol | 2013 |
| 22700489 | Use of kinase inhibitors to correct οF508-CFTR function. | Mol Cell Proteomics | 2012 |
| 23074266 | TWEAK and cIAP1 regulate myoblast fusion through the noncanonical NF-κB signaling pathway. | Sci Signal | 2012 |
| 21303981 | Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells. | Cancer Res | 2011 |
| 22014571 | Virus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell death. | Cancer Cell | 2011 |
| 21733693 | Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup. | Bioorg Med Chem Lett | 2011 |
| 19028424 | Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines as EGFR and ErbB-2 inhibitors. | Bioorg Med Chem Lett | 2009 |
| 19111461 | Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors. | Bioorg Med Chem Lett | 2009 |
| 19101143 | Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R). | Bioorg Med Chem Lett | 2009 |
| 19208477 | Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors. | Bioorg Med Chem Lett | 2009 |
| 18287036 | 6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases. | Proc Natl Acad Sci U S A | 2008 |
| 18842405 | Dual EGFR/ErbB-2 inhibitors from novel pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines. | Bioorg Med Chem Lett | 2008 |
| 17560786 | Synthesis and evaluation of potent and selective beta3 adrenergic receptor agonists containing heterobiaryl carboxylic acids. | Bioorg Med Chem Lett | 2007 |
| 16640337 | Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists. | J Med Chem | 2006 |
| 16483772 | Alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitors. | Bioorg Med Chem Lett | 2006 |
| 11806709 | Synthesis and evaluation of potent and selective beta(3) adrenergic receptor agonists containing acylsulfonamide, sulfonylsulfonamide, and sulfonylurea carboxylic acid isosteres. | J Med Chem | 2002 |
| 11112653 | Two general routes to 1,4-disubstituted-2,3,4,5-tetrahydro- 1H-3-benzazepines. | Org Lett | 2000 |
| 7707314 | Synthesis, topoisomerase I inhibitory activity, and in vivo evaluation of 11-azacamptothecin analogs. | J Med Chem | 1995 |
| 7834631 | In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues. | Cancer Res | 1995 |
| 2477715 | A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. | Nature | 1989 |